The lipoprotein scavenger receptor BI (SCARB1) rs10846744 noncoding variant is significantly associated with atherosclerotic disease independently of traditional cardiovascular risk factors. We identified a potentially novel connection between rs10846744, the immune checkpoint inhibitor lymphocyte activation gene 3 (LAG3), and atherosclerosis.
Introduction
The lipoprotein receptor, scavenger receptor class B type I (SR-BI), is a physiologically relevant receptor that modulates cholesterol levels, especially HDL-cholesterol (HDL-C), in mice and humans (1) (2) (3) (4) (5) (6) (7) . We previously showed that the rs10846744 SNP within the SR-BI gene, SCARB1 (12q24.31), was significantly associated with subclinical atherosclerosis (SCA), myocardial infarction (MI), and cardiovascular disease (CVD) in male participants of the Multi-Ethnic Study of Atherosclerosis (MESA) (5, 6) . Specifically, homozygous carriers of the rs10846744 risk genotype (CC) had significantly increased odds for MI and CVD, and in a multivariable regression model this association was not attenuated by inclusion of traditional CVD risk factors such as age, BMI, hypertension, smoking, renal disease, lipid-lowering medications including statin use, or lipid levels (whether total cholesterol [TC] , LDL-cholesterol [LDL-C], HDL-C, or triglycerides [TGs] ). These findings strongly suggested that other factors or pathways might be causal in the association of rs10846744 with CVD.
The rs10846744 SNP resides within the first intron of SCARB1 and bioinformatic analysis revealed that this SNP is located within an enhancer region, suggesting a region that could transcriptionally regulate genes intrachromosomally or interchromosomally (8) . RNA-Seq was used to evaluate differentially expressed transcripts from lymphocytes isolated from homozygous reference (G) or risk (C) allele carriers. A number of transcriptionally regulated gene candidates emerged, including lymphocyte activation gene 3 (LAG3) that is located at 12p13. 32 .
LAG3 is an Ig superfamily member protein and binds MHC class II with high affinity, and is a potent immune checkpoint inhibitor of activated T cells (9, 10) . It is expressed in B, T, and NK cells, monocytes, and dendritic cells (11) , and its major function is to suppress activated T cells by controlling effector T cell expansion and homeostasis (12) . Cell surface LAG3 protein is cleaved by ADAM10 and ADAM17 metalloproteases, generating plasma LAG3 (13) . In vitro and in vivo murine studies have suggested that plasma can also limit T cell activation and homeostasis by binding to MHC class II on antigen-presenting cells (13) . Importantly, a few clinical studies have shown associations between plasma LAG3 and tuberculosis resistance (14) and breast cancer prognosis (15) .
Since previous analyses showed that traditional CVD risk factors did not attenuate the association of rs10846744 with SCA and CVD (5, 6), we hypothesized that LAG3 protein might affect atherosclerotic risk. Therefore, we used a number of approaches to examine the expression of LAG3 in EBV-transformed B lymphocytes as well as its association with clinical outcomes such as coronary heart disease (CHD). We observed that plasma LAG3 was an independent predictor of HDL-C and CHD risk in the large MESA.
Results
Study demographics. The overall study design, inclusion and exclusion criteria, biospecimen acquisition, and clinical morbidity and mortality for the HALP and MESA cohorts is shown in Figure 1 . As shown in Table 1 , HALP subjects were, on average, middle-aged and predominantly white females. At the time of enrollment none of the subjects were treated with cholesterol-lowering medications whether prescribed or over the counter. The MESA cohort was older and approximately equally distributed between sexes with a larger percentage of patients with Mixed European Descent (40%) compared with African-Americans (26%), Hispanics (22%), and Asians (12%). Since HALP subjects were a priori recruited for fasting plasma HDL-C greater than or equal to 60 mg/dl, the mean HDL-C was 83 mg/dl as compared with the MESA cohort (mean HDL-C 52 mg/dl), since recruitment for this study was based upon age and participants being free from clinical CVD at baseline. Plasma LAG3 levels were significantly different between HALP (8,983 ± 893 pg/ml) and MESA subjects (1,867 ± 54) (P < 0.0001). In MESA participants, the minor allele frequency of rs10846744 differed significantly between patients of Mixed European Descent with Chinese-Americans (P < 0.0001) and with AfricanAmericans (P < 0.0001), but not with Hispanics (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/jci.insight.88628DS1).
Transcriptome analysis reveals differential expression of LAG3 RNA. We first examined transcriptional differences between the homozygous reference (GG homozygous) and risk (CC homozygous) cells cultured under basal (unstimulated) conditions. We explored transcriptional differences of targets residing on chromosome 12, and identified 5 gene transcripts that were significantly downregulated and 3 gene transcripts upregulated in risk cells as compared with the reference cells (Supplemental Table 1 ). Using real-time PCR and Western blotting, we verified that LAG3 RNA and LAG3 protein expression were lower (P = 0.001 Figure 2) . In addition to transcriptome differences on chromosome 12, we also observed interchromosomal transcriptional differences (Supplemental Table 2 ; the full RNA-Seq data set is available in the NCBI's Gene Expression Omnibus [GEO GSE87891]).
LAG3 protein expression is significantly lower in rs10846744 risk cells. At baseline, LAG3 cell surface protein expression was 90% lower in the risk cells as compared with reference cells (P < 0.001) (Figure 2 , A-C). Following stimulation with PMA/ionomycin+IL-4, as compared with baseline levels, LAG3 cell surface protein expression decreased over time in both reference (P < 0.001) and risk cells (combined P = 0.04) ( Figure 2C ). In parallel, as compared with baseline levels, LAG3 protein levels increased over time in the medium from the reference cells (P = 0.03) as compared with no changes observed in the risk cells ( Figure 2D ). With stimulation, cytokine levels in the medium ( Figure 3A ) increased over time as compared with basal levels in both reference and risk cells (TNF-α, P < 0.001 for reference and risk cells, respectively; IL-10, P = 0.02 for reference cells and P < 0.001 for risk cells). TNF-α levels were significantly higher in risk cells (4-fold higher, P = 0.04), while IL-10 levels were lower (53% lower, P = 0.04) as compared with reference cells ( Figure 3B ).
LAG3 protein expression is reduced in lipid rafts and downstream signaling is impaired in rs10846744 risk (CC) cells. Since LAG3 protein has been shown to localize in lipid rafts in activated cells (16), we examined LAG3 protein localization in lipid rafts isolated from unstimulated and stimulated reference and risk cells. LAG3 expression in lipid rafts was lower in risk cells as compared with reference cells (P = 0.03) (Supplemental Figure 3) . We tested whether LAG3 protein reduction affected downstream signaling pathways. Total B cell receptor (BCR) signaling proteins were detected in all cell lines in the absence of stimulation ( Figure 4A ). Following stimulation, none of the phosphorylated targets were detected in the risk cells, while all phosphorylated targets were expressed in the reference cells compared with the unstimulated condition p-CD79A (P = 0.04), p-CD19 (P = 0.04), p-SYK (P = 0.005), p-LYN (P = 0.001), p-PLCγ2 (P = 0.004) and p-PKCβ (P = 0.003). Similar findings were observed of BCR phosphosignaling in all 3 independent reference and all 3 independent risk cells (Supplemental Figure 4) . 
C L I N I C A L M E D I C I N E
Overexpression or silencing of LAG3 protein impacts downstream signaling pathways. To directly assess the effect of LAG3 protein on phosphosignaling, we performed experiments wherein LAG3 was (a) overexpressed in risk cells or (b) silenced in reference cells. LAG3 overexpression in basal or stimulated risk cells was associated with increased levels of phosphorylated targets (P = 0.04 for p-LYN; P = 0.03 for p-PKCβ in unstimulated cells and P = 0.01 for p-LYN; P = 0.01 for p-PKCβ in stimulated cells) as compared with control cells (these being cells that were transfected with empty vector) ( Figure 4B ). LAG3 protein silencing was associated with lower levels of phosphorylated targets (P = 0.002 for p-LYN; P = 0.009 for p-PKCβ in stimulated cells) in the reference cells as compared with control cells ( Figure 4C ). We stimulated overex- Top left panel represents pooled data (mean ± SEM) of 3 independent experiments from the reference (GG-003) cells, each experiment performed with triplicate samples (n = 9, P < 0.001 compared with baseline). Top right panel represents pooled data (mean ± SEM) from 3 independent reference cell lines (n = 18, P < 0.001 compared with baseline). Bottom left presents pooled data (mean ± SEM) of 3 independent experiments from the risk (CC-008) cells, each experiment performed with triplicate samples (n = 9, P = 0.06). Bottom right panel represents pooled data (mean ± SEM) from all the risk cell lines (n = 15, P = 0.04). (D) Changes in LAG3 protein levels in the media over time following cocktail (PMA/ionomycin+IL-4) stimulation in reference-expressing and risk-expressing cells. Top panel represents pooled data (mean ± SEM) of 3 independent experiments from the reference (GG-003) cell line, each experiment performed with duplicate samples (n = 6, *P = 0.03 compared with baseline), and from pooled data (mean ± SEM) of 3 independent experiments from the risk (CC-008) cell line, each experiment performed with duplicate samples (n = 6, P ≥ 0.05, not significant). Bottom panel represents pooled data (mean ± SEM) from all the reference cell lines (n = 12, P ≥ 0.05, not significant) and pooled data (mean ± SEM) from all the risk cell lines (n = 10, P ≥ 0.05, not significant). Quadratic polynomial statistical analyses were performed to test significance.
pressing LAG3 risk cells separately with PMA/ionomycin+IL-4 or CD40 ligand and found that p-CD79A and p-PKCβ, which are specific to BCR-stimulated signaling and not CD40L signaling, were not activated in mock vector risk cells, but were now activated in cells overexpressing the LAG3-GFP construct (Supplemental Figures 5 and 6 ).
Homozygous HALP carriers of the rs10846744 risk allele (CC) had significantly lower plasma LAG3 protein levels. We determined if LAG3 protein levels would be significantly different in plasma isolated from HALP participants. In binary analysis, plasma LAG3 protein levels were significantly lower in carriers homozygous for the risk allele (n = 22; median [first quartile; third quartile]: 1,949 [380; 5,468] pg/ml; P < 0.0001) as compared with subjects homozygous for the reference allele (n = 103; 6,907 [3,399; 10,794]) or heterozygous subjects (GC) (n = 24; 6,902 [3,787; 10,927]) ( Figure 5 ; plasma LAG3 shown as log-transformed). We further analyzed the association of race/ethnicity with plasma LAG3 levels, and found that plasma LAG3 levels were significantly lower in African-Americans (n = 22; 2,772 [380; 7,336] pg/ml; P = 0.004) compared with those of Mixed European Descent (n = 101; 6,184 [3,437; 10,809] ), Asians (n = 7; 9,602 [3,273; 20,078] ), or Hispanics (n = 6; 7,723 [4,105; 12,767 ]) ( Figure 6 ; plasma LAG3 shown as log-transformed). Multivariable linear regression analysis with adjustment for age, sex, and race/ethnicity showed that race (P = 0.009) and SCARB1 rs10846744 (P < 0.0001) remained as significant independent predictors of plasma LAG3 levels.
Race/ethnicity, SCARB1 rs10846744 and other covariates are independent predictors of plasma LAG3 levels in MESA. In binary analysis, plasma LAG3 protein levels were significantly higher in carriers homozygous for the risk allele (n = 974; median [first quartile; third quartile]: 610 [240; 1,892] pg/ml; P < 0.0001) as compared with subjects homozygous for the reference allele (n = 2,448; 454 [216; 1,252] pg/ml) or heterozygous subjects (GC, n = 2,185; 485 [251; 1,130] pg/ml) ( Figure 7 , plasma LAG3 shown as log-transformed). We analyzed the association of race/ethnicity with plasma LAG3 levels, and found that plasma LAG3 levels were significantly higher in African-Americans (n = 1,428,507 [202; 1,971] pg/ml) and Chinese-Americans In a fully adjusted model, race (P = 0.0005), age (P = 0.003), lipid medications (P = 0.03), rs10846744 genotype (P = 0.002), and smoking status (P < 0.0001) were retained as independent predictors of plasma LAG3 levels ( Table 2 ). Plasma LAG3 (P < 0.007) remained an independent predictor of HDL-C levels even with adjustment by age (P = 0.006), sex (P < 0.0001), BMI (P < 0.0001), TG (P < 0.0001), alcohol use (P < 0.0001), hemoglobin A1c (Hgb A1c ) (P = 0.01), and systolic BP (P = 0.03) ( Table 3) .
Logistic multivariable regression analysis revealed that plasma LAG3 was not significantly associated with subclinical atherosclerosis (common carotid intimal medial thickness [cIMT]) (P = 0.25) or coronary artery calcium score (CAC) (P = 0.062) (Supplemental Table 3 ). Logistic multivariable regression analysis revealed that, in addition to traditional risk factors such as age (P < 0.0001), sex (P < 0.0001), systolic BP (P = 0.0002), LDL-C (P = 0.02), TC (P = 0.04), lipid medications (P = 0.002), Hgb A1c (P = 0.03), and smoking (P = 0.05), plasma LAG3 (beta -0.078, odds ratio [OR] 1.15, P = 0.02) was an independent predictor of CHD (Table 4) , but not for all-cause mortality.
The prevalence of participants within the MESA cohort with HDL-C greater than or equal to 60 mg/dl was 26%, and within this group, the prevalence of CHD was 4% and not significantly different between the race/ ethnic groups (Supplemental Table 4 ). HDL-C levels in subjects with CHD (n = 55, 72.4 ± 1.6 mg/dl) were not significantly different compared with subjects without CHD (71.8 ± 0.3 mg/dl, n = 1,387, P = 0.71). However, plasma LAG3 levels were 2-fold lower in subjects with CHD (843.3 ± 540.1 pg/ml, n = 55) as compared with subjects without CHD (1,828 ± 107.6 pg/ml, n = 1,386, P = 0.04). In a logistic regression analysis, plasma LAG3 (beta -0.212, OR 1.45, P = 0.004), age (P = 0.006), sex (P = 0.001), and diastolic BP (P = 0.03) were retained as independent predictors of CHD (Table 5) .
We examined whether plasma LAG3 in the MESA cohort would significantly affect CHD risk prediction in comparison with the Framingham risk score (17) . As shown in Table 6 , plasma LAG3 increased CHD risk prediction in comparison with the Framingham risk score (P = 0.039). When the model included adjustment for study sites, race, and principal components (PCs) of ancestry, plasma LAG3 remained significant as a CHD risk predictor (P = 0.044) Given that we had observed a significant correlation between LAG3 and inflammatory markers from cultured B cells, we investigated whether plasma LAG3 was associated with inflammatory markers available in the MESA datasets. As shown in Table 7 , following multivariable regression analysis plasma LAG3 was positively associated with IL-10 (P < 0.0001). 

Discussion
The rationale for recruiting HALP subjects was to identify subjects with SCARB1 SNPs that were significantly associated with increased risk for atherosclerotic disease. We were able to identify significant associations of certain common SCARB1-coding SNPs with decreased expression and function of SR-BI protein (18) . The rs10846744 SNP is significantly associated with atherosclerotic disease and it is a noncoding SNP residing in an enhancer region (6) . Because the association of rs10846744 with CVD remained significant after multivariable regression analysis and in an effort to identify the pathway linking the association of rs10846744 with subclinical atherosclerosis and CVD, we used RNA-Seq and identified LAG3 RNA as a major target since its expression was significantly lower in homozygous carriers of the rs10846744 risk (CC) allele. LAG3 protein deficiency altered phosphosignaling and enhanced a proinflammatory intracellular state as compared with reference-expressing (GG) cells (Figure 4 ). In the HALP subjects, we showed that plasma LAG3 protein levels were significantly lower in homozygous carriers of the rs10846744 risk allele. When stratified by race/ethnicity, and regardless of genotyping, plasma LAG3 protein levels were lower in African-Americans as compared with Caucasian subjects. With multivariable regression adjusting for age, sex, and race, rs10846744 remained as an independent predictor of plasma LAG3 levels.
The LAG3 gene is located near the CD4 locus and LAG3 protein competes with CD4 by binding with higher affinity to MHC class II to negatively regulate T cell activation (19, 20) . In murine cells, Kisielow et al. (16) In the pooled analysis, homozygous carriers of the risk rs10846744 (CC) allele (n = 974) had significantly higher plasma LAG3 levels compared with heterozygous (n = 2,185) and homozygous reference (GG) allele carriers (n = 2,448). One-way ANOVA, P < 0.0001, total n = 5,607. (22) reported the intracellular distribution of LAG3 protein as being equally distributed between intracellular compartments and the plasma membrane. By using flow cytometry, we confirmed that low levels of LAG3 protein were detected on the cell surface of risk-expressing cells regardless of stimulation conditions (Figure 2 ). However, LAG3 protein was expressed on the cell surface in unstimulated reference cells and levels decreased significantly after stimulation. In addition, since cell surface LAG3 is subject to cleavage by metalloproteases (13), we also observed significantly higher levels of soluble LAG3 protein in the culture media from reference-expressing cells as compared with the risk cells. Consistent with Huard et al. (9), we observed higher secretion levels of TNF-α from risk-expressing cells, demonstrating these cells exhibited a heightened state of inflammation.
LAG3 protein is one of a few important immune checkpoint inhibitors, including programmed cell death protein 1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) (23-28). There has been a considerable amount of interest in PD-1 and CTLA-4 blockade, with biologicals such as pembrolizumab and ipilimumab approved by the FDA for clinical use for advanced melanoma (29-31). Snyder et al. (32) examined the genetic basis for clinical responsiveness to CTLA-4 blockade in subjects with malignant melanoma, finding that some subjects treated with CTLA-4 blockade derived minimal benefit. There is now a phase 1 clinical trial examining the safety and efficacy of anti-LAG3 monoclonal therapy alone and in combination with anti-PD1 in subjects with solid tumors (33) . Our study now demonstrates a potentially novel connection between the SCARB1 rs10846744 SNP and LAG3 RNA and LAG3 protein, showing that carriers for this SNP have lower cellular expression of LAG3 protein and might not be as responsive to immunomodulatory therapy for malignancy.
Bu et al. (34) reported increased atherosclerosis and lesional activated CD4 + and CD8 + T cells in mice deficient in PD-1/PDL-1 and LDLR -/-when fed a western diet as compared with control LDLR +/+ mice. Cochain et al. (35) observed similar findings as well as showing that a proinflammatory state predominates despite expansion of Tregs in PD-1-null mice. We now report that in MESA subjects plasma LAG3 was inversely associated with increased CHD but not with SCA or CAC. When MESA subjects were stratified by HDL greater than or equal to 60 mg/dl, we observed a and African-Americans (n = 1,428) had significantly higher plasma LAG3 levels compared with people of Mixed European Descent (n = 2,282) and Hispanics (n = 1,275) (P < 0.0001) and were not significantly different from each other. There were no significant differences in plasma LAG3 levels between patients of Mixed European Descent and Hispanics. One-way ANOVA, P < 0.0001, total n = 561.
prevalence of HALP within the entire MESA population at 26%. We did not observe a significant difference between HDL-C levels in subjects with or without CHD, but did observe 2-fold lower plasma LAG3 levels in MESA subjects with HALP and CHD compared with subjects without CHD. Consistent with what was observed in the in vitro experiments ( Figure 3B ), low plasma LAG3 levels were significantly associated with low circulating levels of IL-10 in the MESA participants. A connection between LAG3 and IL-10 has been shown by Gagliani et al. (36) , by which these investigators identified cell surface markers CD49b and LAG3 as markers of Treg type I cells that secrete IL-10. Thus, it seems plausible that low plasma LAG3 is significantly associated with low plasma IL-10. The HALP cohort is a unique population of healthy subjects recruited based on high HDL-C levels (≥ 60 mg/dl) (4). Fasting plasma samples were obtained at 1 visit and thus the data are representative of a cross-sectional study, as is true for the MESA samples. The results from the in vitro studies were obtained from EBV-transformed B cells.
In summary, our study shows a potentially novel connection between rs10846744 and LAG3 RNA and LAG3 protein expression and LAG3 with HDL and CHD, supporting further studies examining the intersection of this important immune checkpoint inhibitor on T cell activation, HDL metabolism, and increased risk for CVD. Moreover, plasma LAG3 levels could be informative in the risk stratification for patients with HALP, as it is now becoming clear that current pharmacologic efforts to raise HDL-C levels have not led to improved CVD outcomes (37) (38) (39) . It is compelling that plasma LAG3 levels might be an excellent biomarker for risk stratification in subjects with HALP, especially since we found that plasma LAG3 provided additional information about CHD risk prediction compared with the Framingham risk score. 
C L I N I C A L M E D I C I N E
Methods
Study subjects
HALP participants. Community-dwelling adults between the ages of 18 and 81 years with fasting plasma HDL-C levels greater than or equal to 60 mg/dl (HALP) were enrolled in this ongoing clinical study (4) . The rationale for recruiting HALP subjects was to identify subjects with SCARB1 variants causally linked to increased atherosclerotic risk, which we have now shown with 2 variants, rs4238001 and rs10846744 (6, 18) . Subjects consented to provide overnight fasting blood samples for analysis of lipid profile, DNA analysis for SCARB1 genotyping, and lymphocyte isolation from buffy coats (4) .
MESA participants. The rationale for replicating plasma LAG3 associations in the MESA cohort was the fact that MESA is a large, racially/ethnically diverse study of the natural history of atherosclerotic disease in adults with some collection of risk factors and biomarkers that are identical to those in the HALP study (lipid measurements, rs10846744 genotyping, and plasma LAG3 levels), while having endpoints that are not available in HALP (cIMT, CAC, CHD outcomes, and all-cause mortality) (40) Regression models were adjusted for age, sex, study site, race, and principal components of ancestry. All outcome variables and plasma LAG3 were log transformed. sTNFαR, soluble TNF-α receptor; hs-CPR, high-sensitivity C-reactive protein.
Materials and experimental assays
Details are provided in the Supplemental file.
Genetic analysis in MESA
Genotyping for rs10846744 in MESA was completed on the CardioMetabochip, a custom genotyping array composed of SNPs selected to be associated with type 2 diabetes mellitus and obesity-related traits. PCs of ancestry were computed within race/ethnic groups using the full set of CardioMetabochip genotypes using SMARTPCA (41).
Statistics
One-way ANOVA was used for testing group differences, and 2-sided Student's t test was used for 2-sample analysis. Quadratic polynomial regression analyses were performed to allow for a nonlinear relationship with time. A P value less than 0.05 was considered significant. Linear regression analyses in HALP were performed for the log-transformed outcomes of LAG3 levels within race/ethnic groups, each covariate adjustment for age and sex, and with additional adjustment for race/ethnic group in pooled analysis. In MESA, linear regression analyses with pooled samples used a fully adjusted model for race, PCs of ancestry, age, sex, study site, Hgb A1c , BMI, lipids (TC, LDL-C, HDL-C, TG), lipid-lowering medications, systolic and diastolic BP, pack years of smoking and, in some analyses, rs10846744 genotype and alcohol use.
Study approval
For HALP participants, subjects provided written informed consent prior to their participation in the study, and this study was approved by the institutional review boards at the Johns Hopkins University School of Medicine, Baltimore, Maryland, USA and the University of Connecticut School of Medicine. For MESA participants, study subjects provided written informed consent prior to their participation in the study and the MESA study was approved by the institutional review boards at each participating institution, including the Johns Hopkins 
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